Safety and Feasibility Study of Cell Therapy in Treatment of Spinal Cord Injury

Inclusion Criteria: * Men and women between age 18 and 50 * Paraplegics and quadriplegics with complete or incomplete spinal cord injuries. * Willingness to undergo bone marrow derived autologous cell therapy. * Ability and willingness to make regular visits to hospital and follow ups during the protocol procedure and comply with all medical instructions * Traumatic Injury of spinal cord with complete or partial damage by Magnetic Resonance Imaging (MRI) and injury level below C4 * ASIA impairment scale from A - C * Must have proof of health insurance in country of residence. * Signed informed consent Exclusion Criteria: * Pre- existing or current systemic disease such as lung, liver (exception: history of uncomplicated hepatitis A), gastrointestinal, cardiac, Human Immunodeficiency Virus (HIV) * History of life threatening allergic- or immune-mediated reaction * Hemodynamic instability * Peripheral muscular dystrophy * Lactating or pregnant woman * Women capable of childbearing unwilling to use multiple forms of contraception * Alcohol drug abuse /dependence * Positive test result for hepatitis A and Hepatitis B OR C * Major-traumatic brain injury and psychiatric illness * Open injuries * Active infectious diseases * Life expectancy of less than one year due to terminal condition * Neurodegenerative diseases * Primary hematologic diseases * Any of the following medications that cannot be discontinued one week prior to the first stem cell administration and throughout the course of treatment. (1 week before visit 2 through one week after visit 12) * Antibiotics * Antifungals * Antivirals * Blood thinners (to avoid bleeding risk during bone marrow aspiration and IT procedures) * High doses of Vitamin D or fish oils (since these might prolong bleeding times) * Bone reflecting increased risk for spinal puncture * Hepatic dysfunction * Other medical complications that contraindicate surgery, including major respiratory complications * Participation in another clinical trial * Coagulopathies * Uncorrected coagulopathy during the baseline period defined as: International Normalized Ratio (INR) \> 1.4; Partial Thromboplastin Time (PTT) \> 35 sec; Platelet Count (PLT) \< 100,000. * Pre-injury history of seizure disorder and/or neurological impairment where participation in age-appropriate pain rating scales would not be practical or possible * Subject does not sign informed consent form